Completed PHASE3 INTERVENTIONAL 2-arm NCT03736369

Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease (Phase 3)

A Multi-Center, Randomized, Double-Blind, Active-controlled, Parallel-Group, Phase 3, Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease

Sponsor: Daewoong Pharmaceutical Co. LTD.

Conditions Erosive Esophagitis

Interventions DWP14012 40mg DWP14012 40mg placebo Esomeprazole 40mg Esomeprazole 40mg placebo

Updated 7 times since 2018 Last updated: Sep 1, 2020 Started: Dec 13, 2018 Primary completion: Aug 7, 2019 Completion: Aug 7, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Erosive Esophagitis, this trial is completed. The trial is conducted by Daewoong Pharmaceutical Co. LTD. and has accumulated 7 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Oct 2020 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Jun 2020 — Oct 2020 [monthly]

Completed PHASE3

Status: Not Yet Recruiting → Completed
Dec 2018 — Jun 2020 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Daewoong Pharmaceutical Co. LTD.

Data source: Daewoong Pharmaceutical Co. LTD.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea